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Atherosclerosis is characterized by cholesterol deposition
in the arterial intima, with subsequent plaque formation and
arterial disease. Low-density lipoprotein cholesterol (LDL-
C) plays the most important role in the atherogenesis
process, which is the substrate of cardiovascular disease
and is the leading cause of death worldwide. Several
studies show that a strict control of risk factors, particularly
the reduction of LDL-C levels, is a cornerstone in primary
and secondary prevention of coronary heart disease. Statins
are currently the most effective drugs for lowering LDL-C,
but the discovery of proprotein convertase subtilisin kexin 9
(PCSK9) has opened up new therapeutic options in lipid
management. PCSK9 reduces LDL-receptors’ recycling
resulting in a decrease of LDL-C receptors on the surface of
hepatocytes and an increase of LDL-C levels in plasma.
Obviously, inhibition of PCSK9 has been associated with an
increase of LDL-C receptors with subsequent lowering of
plasma levels of LDL-C. The clinical development of
monoclonal antibodies against PCSK9 has been achieved
through phase I and II studies, and nowadays there are
many ongoing phase III trials with promising preliminary
results. The aim of this review is to update the evidence for
PCSK9 monoclonal antibodies, such as evolocumab,
alirocumab and bococizumab, in LDL-C management
and to discuss their therapeutic perspectives based
on the most recent clinical studies, with attention to side-
effects.
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Introduction
Cardiovascular disease (CVD) is the primary cause of
death worldwide, mainly because of the aging of the
population.1 However, improved control of cardiovascu-
lar risk factors has led, in the last two decades of the 20th
Century, to a consistent reduction in deaths attributable
to coronary heart disease.2 Low-density lipoprotein cho-
lesterol (LDL-C)-lowering therapies have played a
primary role in the reduction of cardiovascular risk and
still remain a mainstay in coronary heart disease (CHD)
secondary prevention. Large randomized clinical trials
show a linear relationship between LDL-C reduction and
a decrease in CVD and the new AHA/ACC guidelines
adopt more and more stringent LDL-C targets.3 Statins
are currently themost effective drugs in reducing LDL-C
levels and except for the ezetimibe, no lipid-modifying
therapy added to statins has been demonstrated to pro-
vide a clinical benefit.4 Moreover an increase from a high
dose to a very high dose of statin leads at best to a further
2% reduction in clinical events, but with the negative
consequences of increased side-effects and decreased
compliance.5 The discovery of proprotein convertase
subtilisin kexin 9 (PCSK9) is a new and promising
therapeutic option in the management of LDL-C levels.6
The aim of this review is to update the evidence regard-
ing PCSK9 antibodies’ treatment in lowering LDL-C
levels and discusses its therapeutic prospectives based on
the most recent clinical trials.
Features of proprotein convertase subtilisin
kexin 9
PCSK9 is a protein secreted mostly from the liver,
encoded by the PCSK9 gene. In 2003, Seidah et al.7
identified the ninth member of the proprotein convertase
family (PCSK9) and in the same year another group
showed a possible involvement of PCSK9 in regulating
cholesterol metabolism.8 Berberine, a quaternary
ammonium salt of protoberberine, is a substance found
in plants such as of the genus Berberis (hence the name),
usually in the roots, rhizomes, stems and bark, charac-
terized by an upregulating activity on low-density lipo-
protein receptor (LDLR).9 PCSK9 binds the epidermal
growth factor-like repeat A (EGF-A) domain of the
LDLR positioned onto the surface of the hepatocyte,
and degrades it intracellularly.10,11 Reduced LDLR
levels result in decreased metabolism of LDL-C, which
could lead to hypercholesterolemia. Variants of PCSK9
can reduce or increase circulating cholesterol. LDLR
present on the surface of liver cells binds the circulating
LDL-C, removes it from the blood and takes it inside the
cells. When PCSK9 binds to an LDLR, the receptor is
destroyed along with the LDL particle, but this does not
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happen if PCSK9 concentrations are intrinsically low. In
this case the receptor can return to the surface of the cell
and remove more cholesterol.12 LDL-C levels lower than
normal and subsequently reduced incidence of CHD
have been observed in humans affected by PCSK9
mutations with loss of function.13 On the contrary partici-
pants with PCSK9 mutations with gain of function have
been shown to suffer from hypercholesterolemia with the
development of premature CHD.8 Moreover statins
seem to increase PCSK9 levels, particularly in patients
affected by familial hypercholesterolemia.14 PCSK9
mutations, in fact, have been associated to autosomal
dominant familial hypercholesterolemia, accounting for
1–2% of all familial hypercholesterolemia cases.8,12 Early
diagnosis of familial hypercholesterolemia is essential to
reduce morbidity and mortality from premature athero-
sclerosis with an adequate lipid-lowering therapy.15 The
loss-of-function mutations of PCSK9 have been associ-
ated with a decrease of LDL-C levels. It has been
estimated that the loss of one functional PCSK9 allele
could prevent 88% of CVD events.16 By inhibitingHMG-
CoA¼ 3-hydroxy-3-methyl-glutaryl-CoA reductase, on
the other site, statins increases the number of LDLR
on the hepatic cell’s surface and the level of PCSK9
increases to regulate the number of LDL-receptors,
possibly contributing to a limitation on the effectiveness
of statin in reducing LDL-C levels. Several clinical
studies showed that administration of ezetimibe 10mg/
day is efficient in increasing the lipid-lowering effect of
any statin by 15–26%, with the possibility to reach LDL-
C threshold values recommended for an optimal control
of cardiovascular risk.17 This double inhibition, operated
at the level of the enterocyte and hepatocyte, is up to date
the best therapeutic option in the management of lipid
disorders, preserving also the numerous pleiotropic
effects of statins. PCSK9 inhibitors, unlike statins, may
not have pleiotropic benefits on the unstable plaque but
several studies indicate that PCSK9 promote inflam-
mation, endothelial dysfunction, and hypertension with
a mechanism independent of LDLR.18 Additional
research is needed to clarify the potential benefit of
PCSK9 inhibition.
Clinical trials with proprotein convertase
subtilisin kexin 9 inhibitors
Three pharmaceutical companies are producing mono-
clonal antibodies focused on PCSK9, which represents
the most promising approach in reducing LDL-C levels,
considering that a single injection can lower PCSK9
levels by up to 100% for more than 7 days. Amgen and
Sanofi have conducted phase I and phase II clinical trials,
and have demonstrated the safety and efficacy of the
treatment confirming a 60–70% reduction of LDL-C
with subcutaneous injections every 2 weeks. Possible
side-effects consist of local reactions at injection sites.
The possibility of serious side-effects from PCSK9 is
conceivable because PCSK9 has been postulated to play
role in different pathways as including neuronal apopto-
sis, regulation of sodium channels, pancreatic islet cell
function and nervous system development.19 However,
humans affected by PCSK9 loss-of-function mutations or
PCSK9-deficient mice do not appear to have any deficit,
and it has been shown that people with LDL-C levels as
low as 15mg/dl are healthy.20
The PROFICIO program, the ODYSSEY program and
the SPIRE program are ongoing studies with PCSK9
inhibitors. Patients at very high risk are being evaluated
in the FOURIER trial, whereas patients hospitalized for
acute coronary syndrome in the last 12 months with poor
control of LDL-C levels are being evaluated in the
ODYSSEY OUTCOMES trial.
Evolocumab
Evolocumab was tested in mice and monkey models
demonstrating reductions of serum LDL-C and total
cholesterol without adverse effects and no evidence of
toxicity.21,22 In phase I studies, moreover, AMG 145
reduced LDL-C levels by up to 66% in healthy and
hypercholesterolemic statin-treated patients with mini-
mal adverse effects.23 The Program to Reduce LDL-C
and Cardiovascular Outcomes Following Inhibition of
PCSK9 in Different Populations (PROFICIO) consists
of different phase II and III trials assessing LDL-C
reduction and CVD outcomes. The LAPLACE-TIMI
57, a phase II trial, designed to assess the safety and
efficacy of AMG 145 when added to statin therapy in
patients with hypercholesterolemia, demonstrates the
efficacy and safety of AMG145 in hypercholesterolemic
patients treated with statins and has had a major role in
determining dose selection and design of phase III car-
diovascular outcome trials.24 In the GAUSS trial, con-
ducted in statin-intolerant patients, subcutaneous
administration of monoclonal antibodies against PCSK9
reduced LDL-C levels with short-term tolerability.25
The RUTHERFORD trial evaluated the safety and
efficacy of AMG 145 in patients with heterozygous famil-
ial hypercholesterolemia (HeFH) with LDL-C of at least
2.6mmol/l (100mg/dl) despite statin therapy with or
without ezetimibe. In this study patients were random-
ized 1:1:1 to AMG 145 350 mg, 420mg or placebo-
administered subcutaneously every 4 weeks with sub-
stantial reductions in LDL-C, up to 73%, in patients with
HeFH with minimal adverse events and good tolerabil-
ity.26 The MENDEL trial shows that AMG145 adminis-
tered in doses from 70 to 420mg reduced LDL-C levels
in every group of patients treated, by up to 48%. More-
over, no deaths or serious treatment-related adverse
events were reported, assessing the use of AMG145 in
long-term and larger studies.27 The data from these four
phase II trials were evaluated in the OSLER trial, a
subsequent phase III study, which demonstrated that
evolocumab administered every 4 weeks shows contin-
ued efficacy, safety and good tolerability over 1 year in
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patients with hypercholesterolemia.28 The GAUSSII trial
evaluated evolocumab 140mg administered every 2
weeks and 420mg every 4 weeks in patients with hyper-
lipidemia with statin intolerance and showed a reduction
of LDL-C levels of up to 53%, with a rate of adverse
events, particularly muscle based, of 12%.29 The
LAPLACEII shows, in patients with hyperlipidemia
treated with medium- or high-intensity statin therapy
or with ezetimibe, a reduction of LDL-C levels of up to
75% by adding evolocumab 140mg every 2 weeks or
420mg in a monthly dose.30 The DESCARTES trial
shows the strong efficacy in reducing both PCSK9 levels
(by up to 90%) and LDL-C levels (by up to 57%) in 1
week in patients with a baseline LDL-C of at least 75mg/
dl (1.9mmol/l) undergoing treatment with evolocumab
420mg monthly, with an adverse profile similar to
placebo.31 The MENDELII trial assessed monotherapy
with evolocumab compared with ezetimibe or placebo in
patients with hyperlipidemia, and showed a reduction of
LDL-C levels up to 57%, with a rate of adverse events
comparable to placebo.32 The RUTHERFORDII trial
assessed efficacy and safety of evolocumab 140mg every
2 weeks or 420mg every 4 weeks in patients with with a
reduction of LDL-C levels up to 65% after 3 months of
treatment.33 Finally the TESLA-B trial assessed efficacy
and safety of evolocumab in patients with homozygous
familial hypercholesterolemia, showing a reduction of
LDL-C levels up to 30% after 3 months of treatment.
Phase II and phase III studies with evolocumab are
reported in Table 1.34
Alirocumab
Several phase I and phase II studies have shown the
efficacy and safety of alirocumab in lowering LDL-C
levels, with rapid and substantial dose-dependent
reduction and minimal adverse effects. Stein and col-
leagues35 demonstrated that monoclonal antibody against
PCSK9, REGN727/SAR236553 (REGN727), signifi-
cantly reduces LDL-C levels in healthy volunteers and
in patients with familial or nonfamilial hypercholester-
olemia by up to 64%. McKenney and colleagues36
observed that when added to atorvastatin, SAR236553
reduces LDL-C by 40–72%, and also in this case a dose
and administration time-dependent effect was demon-
strated. Interestingly a plateau effect for the higher doses
was evidenced, suggesting that circulating and not intra-
cellular PCSK9 is responsible for LDL-C regulation.
Subsequently, Stein and colleagues37 showed that
REGN727, 150, 200 or 300mg administered every
4 weeks, or 150mg every 2 weeks, was well tolerated
and led to further LDL-C reduction in patients with
heterozygous familial hypercholesterolemia with elev-
ated LDL-C levels despite statin therapy with or without
ezetimibe. The most common adverse event was injec-
tion site reaction with only one drop-out patient. Roth
and colleagues38 conducted a randomized trial with
patients affected by primary hypercholesterolemia and
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showed that adding SAR236553 to either 10mg of
atorvastatin or 80mg of atorvastatin led 90% of patients
treated to achieve LDL-C levels less than 70mg/dl
(1.8mmol/l), compared with only 17% of those under
high-intensity statin therapy. Gaudet and associates,39
moreover, demonstrated that alirocumab 150 adminis-
tered twice per month resulted in a consistent reduction
of lipoprotein(a), which could contribute in part to LDL-
C lowering. The ODYSSEY program is a large phase III
study with alirocumab and includes 14 global trials
covering 23 500 participants, divided into three groups:
HeFH, hypercholesterolemia in high-risk population and
additional studies looking at monotherapy, statin intol-
erance and comparisons to atorvastatin or rosuvastatin
with or without ezetimibe. The ODYSSEY FH I, II and
HIGH FH trials assessed safety and efficacy of alirocu-
mab 75mg every 2 weeks in patients with HeFH and
high risk or very high risk for CVD, showing a reduction
of LDL-C up to 48% to week 24, with a similar rate of
adverse events compared with placebo.40 Alirocumab was
demonstrated as superior to LDL-C-lowering therapies
also in the ODYSSEY MONO, which compared this
monoclonal antibody against PCSK9 versus ezetimibe,
showing an LDL-C levels reduction of up to 54% at
24 week.41 The ODYSSEY COMBO I and II trials
evaluated safety and efficacy of alirocumab added to
statin therapy as high as tolerated in hyperlipidemic
high-risk patients compared with ezetimibe, resulting
in an LDL-C level reduction of up to 50% at a dose
of 75mg twice a month. Similar rates of adverse events
were also evidenced compared with ezetimibe.42,43 The
ODYSSEY LONG TERM trial evaluated the safety and
tolerability of alirocumab in HeFH, high- and very high-
risk patients (2341 under the highest tolerated statin
therapy), showing LDL-C reduction of up to 61%,
80% of patients treated at target, similar adverse events
compared with placebo but, moreover, a lower rate of
cardiovascular events in alirocumab arm compared with
placebo.44 The ODYSSEY ALTERNATIVE evaluated
the efficacy and safety of alirocumab compared with
ezetimibe in very high-risk patients intolerant to statin
with an LDL-C reduction of up to 45%, with 61% of
patients at target and a lower rate of discontinuation of
therapy compared with ezetimibe.45 A similar trend has
been observed in the COMBO II trial with maintenance
of a 50% decrease in LDL-C at 52 weeks and similar data
were confirmed also by the results from 78 weeks’ follow-
up of the ODYSSEY LONG TERM.44 Further
results are expected from the other ongoing trials
ODYSSEY CHOICE I and II, ODYSSEY OPTIONS I
and II, ODYSSEYOUTCOMES and ODYSSEYOLE.22
Phase II and phase III studies with alirocumab are
summarized in Table 2.
Bococizumab
In addition to the PROFICIO and ODYSSEY programs,
other trials are evaluating the potential role of
bococizumab (RN316) in Reducing the Occurrence of
Major Cardiovascular Events in High Risk Subjects
(SPIRE programs). SPIRE I and II (https://clinicaltrials.-
gov/ct2/show/NCT01975376, https://clinicaltrials.gov/
ct2/show/NCT01975389) are evaluating the efficacy
and safety of bococizumab, respectively in high-risk
patients with baseline LDL-C between 100mg/dl
(2.6mmol/l) and 70mg/dl (1.8mmol/l) and in high-risk
patients with a baseline LDL-C not at target (>100mg/d
or >2.6mmol/l). Other ongoing phase II trials are
represented by the SPIRE-LDL (https://clinicaltrials.-
gov/ct2/show/NCT01968967) and the SPIRE HR
(https://clinicaltrials.gov/ct2/show/NCT01968954), in
patients with primary hyperlipidemia or mixed dyslipi-
demia at risk of cardiovascular events, and the SPIRE
HF, in patients with heterozygous HeFH (https://clin-
icaltrials.gov/ct2/show/NCT01968980). The studies are
ongoing and further results are expected.
Side-effects
Allergic reactions at the site of the injection are the most
common side-effect as reported by many trials, with a
similar event rate compared with placebo. The clinical
trials with evolocumab reported no differences in the
occurrence of side-effects compared with placebo.25–35
Similar data are reported from ODYSSEY FH I, II and
HIGH FH.40 The ODYSSEY MONO reported a rate of
side-effects similar to placebo.41 The COMBO I and the
ODYSSEY LONG TERM, on the contrary, assessed a
risk of local site reaction inferior for alirocumab when
compared with lipid-modifying therapies (respectively
5.3 vs. 2.8%, 5.9 vs. 4.2%).42,44 Moreover site reactions
were mild, transitory and did not cause study drug
discontinuation. Finally the ODYSSEY ALTERNA-
TIVE assessed a rate of study drug discontinuation
because of adverse events lower with alirocumab com-
pared with ezetimibe.45 The OSLER trial reported
similar rates of myalgia with alirocumab compared with
lipid-modifying therapies (6.4 vs. 6.0%) but a higher rate
was found by the ODYSSEY LONGTERM in the study
group compared with placebo as reported (5.4 vs. 2.9%).
A higher risk of developing neurocognitive disorders
was reported by the OSLER trial (0.9 vs. 0.3%), a low
percentage not differing from the one reported in the
subgroup with very low LDL, but many data are con-
troversial and a further and longer follow-up is needed.46
They seem in any case not to be related to very lowLDL-
C levels.28 Regarding this concern, there have been
reports of healthy participants with LDL-C levels as
low as 15mg/dl due to genetic mutation.20 There are
lots of concerns regarding the very low LDL-C levels (up
to 0mmol/l!) reached in these clinical trials. The
COMBO I trial, for example, reported patients with
LDL-C levels of 0.4mmol/l, with no evidence of a major
susceptibility to neurocognitive disorders or cardiovascu-
lar events at 18 months.42 Discussion of potential harm
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from very low LDL-C with possible development of
cancer, hemorrhagic stroke and violent death will require
further years of analysis and more evidence from out-
comes trials to show a relationship with low LDL-C.47
Moreover, conflicting data exist regarding the possible
role of PCSK9 inhibitors on glucose homeostasis. In
animal models, in fact, lack of PCSK9 led to cholesterol
accumulation in pancreatic islet beta cells with sub-
sequent impairment of insulin secretion, hyperglycemia
and insulin insufficiency.48 This suggestion has no con-
firmation in humans. In fact, in a large prospective cohort
of patients it was recently demonstrated that the PCSK9
p.R46L LOF variant was not associated with impaired
glucose homeostasis in humans.49 These data are reassur-
ing regarding the safety of PCSK9 inhibitors. PCSK9 is
also expressed in other tissues in addition to the liver,
with functions that are still not totally clarified. For
example, PCSK9 is highly expressed in the intestine,
particularly in the small bowel, where it seems to control
the production of triglyceride lipoproteins and transin-
testinal cholesterol excretion.50 Significant levels of
PCSK9 were found also in kidneys where it seems that
it could play a role in nephrogenesis.51 PCSK9 located in
smooth muscle cells regulates directly LDLR expression
in macrophages with a paracrine action,52 and it seems
also to play a role in determining the content of athero-
sclerotic plaque.53 Finally PCSK9 appears to play a role in
neurogenesis and also in Alzheimer’s disease by inducing
deposition of beta-site amyloid precursor protein.54
Perspectives
Monoclonal antibodies against PCSK9 seem to be well
tolerated, in terms of side-effects, although injections
might not be particularly attractive for lifelong treatment.
Despite this disadvantage, the efficacy of this new thera-
peutic approach is well documented and many patients,
such as those suffering from HeFH, homozygous familial
hypercholesterolemia or those unable to assume statin
therapy owing to side-effects, may benefit from a therapy
with a monoclonal antibody against PCSK9. Moreover,
this approach will lead patients not on target to achieve
stringent LDL-C target levels as recommended by the
European guidelines, to new LDL levels never reached
with the recent even most powerful lipid-lowering
therapy.55 However, the impact of PCSK9 inhibition in
individuals with normal PCSK9 must be clarified.56
Another question regarding these innovative medicines
concerns the cost of therapy. In order to be cost-effective
for patients, the PCSK9-inhibitors would need to cost
around $2400 per year, strikingly lower than what manu-
facturers are currently charging for the two available
drugs, according to a recent report.57 Moreover the cost
of therapy varies depending on whether it is a primary
prevention (as in familial hypercholesterolemia) or sec-
ondary prevention (as in statin-intolerant patients). Actu-
ally estimates of annual price for these new medications
are in a range of 6800–14 600 dollars, and given the great
number of patients potentially eligible for the treatment
with PCSK9 inhibitors, the potential overall cost could be
huge.58 However, further investigations are needed to
clarify the risk of side-effects.
Conclusion
Reduction in LDL-C levels remains a mainstay of
primary and secondary prevention in CVD. Many
patients, including those suffering from HeFH, homo-
zygous familial hypercholesterolemia or with consistent
side-effects from statin may benefit from a lifelong
therapy with monoclonal antibodies against PCSK9. Evo-
locumab, alirocumab and bococizumab seem to be well
tolerated, except for an unattractive local site reaction.
Many aspects on further side-effects of these treatments
need clarification. Further years of analysis and more
evidence from outcomes’ trials are necessary to show
a relationship between low LDL-C and medium-
long-term side-effects.
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